Promoter holding
64.27%
LS
Lasa Supergenerics Limited - Due diligence report
A 360° intelligence report on Lasa Supergenerics: trust score, financial health, credit view, compliance, directors, growth and distress sig…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹349
50% off
New user
Or enjoy up to 50% off with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Lasa Supergenerics — 360° Intelligence Report
Generated from MCA filings & public records62/100
Trust Score
Moderate
Lasa Supergenerics is assessed as Moderate with a Trust Score of 62/100. Lasa Supergenerics is an active public limited indian non-government company incorporated in 2016, operating in the Pharma sector. Reported revenue has declined across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and high financial risk profile.
Report generated on 28 Jun 2026 from the latest processed filings. Lasa Supergenerics Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreModerate
62/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
62/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreCaution Indicated
40/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
45/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
75/100
Board strength, DIN status, churn and network.
Growth ScoreCaution Indicated
40/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
50/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 45/100 Caution Indicated
- Negative operating earnings - debt service depends on external support.
- No open charges - unencumbered balance sheet.
Charges position: 0 open (-) · 3 satisfied (84.64 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Axis Bank Limited | 1 | 48.0 cr |
| Others | 2 | 48.0 cr |
Compliance Score: 62/100 Moderate
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Litigation present in 4 court forum(s).
- 2 auditor resignation(s) filed - latest: Ramanand & Associates on 2018-05-15.
- Delayed payments to MSME suppliers disclosed (95 disclosure(s)).
- 1 active GST registration(s).
Legal cases on record (4)
05
Director Intelligence
Stability score: 75/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| MANALI ROOP BHAGTANI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Umesh Shankar Pawar | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Mitti Jain | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| HARDESH RAJA TOLANI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| EKTA AVTAR GURNASINGHANI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| OMKAR HERLEKAR PRAVIN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| AJAY HARESHLAL SUKHWANI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Mitti Mitesh Jain | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Prathmesh Prakash Chalke | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Varsha Pravin Joshi | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Ketan Bhau Songal | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Pravin Gadalya Lachake | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Yogesh Hari Ughada | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Rekha Hemant Wakh | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 14 directors on the board.
- No disqualified or deactivated DINs.
- 7 director exits in 3 years - high churn.
Director & KMP remuneration (FY 2023)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2023 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Omkar Speciality Chemicals Limited
Subsidiaries
-
Group entities
-
Capital events
5 allotment(s) · 0 transfer(s)
Promoters hold a majority stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Omkar Speciality Chemicals Limited | Holding Company | 74.00% |
Key managerial personnel: Umesh Shankar Pawar (Whole-time director) · OMKAR HERLEKAR PRAVIN (Managing Director)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 40 · Distress 50
Growth signals & trust indicators
Operating for 10+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
Losses deepening year-on-year.
5 director exits within 2 years.
2 auditor resignation(s) on record - review the stated reasons.
MSME payment delays disclosed - latest outstanding 3.14 cr.
4 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence58/100
Review suggested
Suitability as a supplier / customer counterparty.
- Check the compliance flags before onboarding.
- 3 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment48/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- No existing security registered - first-charge position available.
- Compliance gaps should be priced into terms.
Investor view46/100
Mixed indicators
Growth quality and scalability through an investor lens.
- No clear growth signals in the filed years.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events30 Sep 2025
Last AGM held
Annual general meeting
29 Sep 2025
Director ceased
Ketan Bhau Songal
Director ceased
Pravin Gadalya Lachake
Director ceased
Yogesh Hari Ughada
Director ceased
Rekha Hemant Wakh
02 Sep 2025
Director ceased
Prathmesh Prakash Chalke
04 Aug 2025
Director appointed
Ketan Bhau Songal (Director)
Director appointed
Pravin Gadalya Lachake (Director)
Director appointed
Yogesh Hari Ughada (Director)
Director appointed
Rekha Hemant Wakh (Director)
21 May 2025
Director appointed
Prathmesh Prakash Chalke (Additional Director)
31 Mar 2025
Latest balance sheet
Filed with ROC
01 Aug 2024
Director appointed
Varsha Pravin Joshi (Cfo)
25 Jun 2024
Director ceased
Umesh Shankar Pawar
25 Apr 2024
Director ceased
RAVISHANKAR RAMPRASAD KABRA
10
Key Observations
Auto-generated from the data aboveRevenue declined 38% over the last 4 financial year(s).
Net profit margin moved from 1.42 to 2.1x.
Net worth is positive.
14 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
All 3 registered charge(s) stand satisfied - past borrowings repaid.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a majority stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 5 security allotment(s) - amounts available in the full report.
| Company | CIN | Location |
|---|---|---|
| Delight Chemicals Pvt Ltd | U24110AP1989PTC010835 | Piduguralla, Andhra Pradesh, India |
| Sioncpharmaceuticals | U24232AP2008PTC057417 | Visakhapatnam, Andhra Pradesh, India |
| Ambey Iron Private Limited | U13100GA2003PTC003274 | Panaji, Goa, India |
| Agro Phos | L24123MP2002PLC015285 | Indore, Madhya Pradesh, India |
| White 'N' White Minerals Private Limited | U14101RJ1995PTC011231 | Jodhpur, Rajasthan, India |
| Avid Organics Private Limited | U74999DL2000PTC104955 | Delhi, Delhi, India |
| Syntho Chirals Private Limited | U24239TG2004PTC043066 | Hyderabad, Telangana, India |
| Avachemicals | U27100MH1985PTC038183 | Mumbai, Maharashtra, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Lasa Supergenerics before audits and certifications: compliance score 62/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Lasa Supergenerics: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 45/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Mixed indicators. Growth score 40/100, margin trends, ownership structure and peer set for Lasa Supergenerics - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Review suggested. Trust score 62/100, distress signals and MSME payment-delay disclosures - know whether Lasa Supergenerics pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (4 case(s) on record), regulatory flags, charge documents trail and director networks for Lasa Supergenerics - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Lasa Supergenerics an active company?
Lasa Supergenerics has MCA status “Active” with a compliance score of 62/100 (Moderate).
Is Lasa Supergenerics financially healthy?
Lasa Supergenerics has a Financial Health Score of 40/100 (Caution Indicated) based on its filed financial statements.
Should I do business with Lasa Supergenerics?
Its overall Trust Score is 62/100 (Moderate). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Lasa Supergenerics?
The ultimate holding entity is Omkar Speciality Chemicals Limited. 14 active director(s) are on record.
Does Lasa Supergenerics have loans or charges against its assets?
No open charges - all 3 registered charge(s) stand satisfied, indicating past borrowings were repaid.
Is Lasa Supergenerics up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 62/100 (Moderate).
Is it risky to lend to Lasa Supergenerics?
Its Credit Risk Score is 45/100 (Caution Indicated). Banker verdict: Mixed indicators - deeper appraisal suggested.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
